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Abstract
Background: The Epstein-Barr virus (EBV)-encoded EBNA1 protein is expressed in all EBV-associated tumours,
including undifferentiated nasopharyngeal carcinoma (NPC), where it is indispensable for viral replication, genome
maintenance and viral gene expression. EBNA1’s transcription factor-like functions also extend to influencing the
expression of cellular genes involved in pathways commonly dysregulated during oncogenesis, including elevation
of AP-1 activity in NPC cell lines resulting in enhancement of angiogenesis in vitro. In this study we sought to
extend these observations by examining the role of EBNA1 upon another pathway commonly deregulated during
carcinogenesis; namely NF-B.
Results: In this report we demonstrate that EBNA1 inhibits the canonical NF-B pathway in carcinoma lines by
inhibiting the phosphorylation of IKKa/b. In agreement with this observation we find a reduction in the
phosphorylation of IBa and reduced phosphorylation and nuclear translocation of p65, resulting in a reduction in
the amount of p65 in nuclear NF-B complexes. Similar effects were also found in carcinoma lines infected with
recombinant EBV and in the EBV-positive NPC-derived cell line C666-1. Inhibition of NF-B was dependent upon
regions of EBNA1 essential for gene transactivation whilst the interaction with the deubiquitinating enzyme, USP7,
was entirely dispensable. Furthermore, in agreement with EBNA1 inhibiting p65 NF-B we demonstrate that p65
was exclusively cytoplasmic in 11 out of 11 NPC tumours studied.
Conclusions: Inhibition of p65 NF-B in murine and human epidermis results in tissue hyperplasia and the
development of squamous cell carcinoma. In line with this, p65 knockout fibroblasts have a transformed
phenotype. Inhibition of p65 NF-B by EBNA1 may therefore contribute to the development of NPC by inducing
tissue hyperplasia. Furthermore, inhibition of NF-B is employed by viruses as an immune evasion strategy which is
also closely linked to oncogenesis during persistent viral infection. Our findings therefore further implicate EBNA1
in playing an important role in the pathogenesis of NPC.
Background
Epstein-Barr virus (EBV) is a ubiquitous human g-her-
pesvirus that is associated with both lymphoid and
epithelial tumours [1], including undifferentiated NPC
where there is a near 100% association with EBV infec-
tion. Whilst the pattern of EBV latent protein expres-
sion varies in different tumour types the EBV nuclear
antigen, Epstein-Barr nuclear antigen-1 (EBNA1), is
expressed in all EBV-associated malignancies due to its
indispensable role in the maintenance and replication of
the EBV genome via sequence-specific binding to the
viral origin of replication, oriP [2]. Furthermore, as a
DNA binding protein EBNA1 interacts with viral gene
promoters, thereby contributing to the transcriptional
regulation of the EBNAs and of latent membrane pro-
tein 1 (LMP1) [3].
In addition to EBNA1’s functions that depend on its
binding to viral DNA, EBNA1 can also interact with
host cell proteins, including the ubiquitin-specific pro-
tease USP7 which has been implicated in the
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t h es a m er e g i o no fU S P 7a sd op 5 3a n dM D M 2 .T h i s
suggests that EBNA1 can protect against either UV- or
p53-induced apoptosis [4]. Whilst a more direct involve-
ment of EBNA1 in carcinogenesis has been suggested by
the ability of B-cell-directed EBNA1 expression to pro-
duce B-cell lymphomas in transgenic mice [5], other
data are not supportive of such a role [6]. Thus, studies
using dominant-negative EBNA1 in an LCL with an
integrated EBV genome revealed that EBNA1 had no
effect on cell growth or cellular gene expression [7]
whilst other work in which EBNA1 was expressed in
Akata BL cells previously cleared of EBV infection
demonstrated that EBNA1 expression alone is not suffi-
cient to confer tumourigenic potential [8,9]. However, in
s u p p o r to far o l ef o rE B N A 1i nc a r c i n o g e n e s i sw ea n d
others have demonstrated that EBNA1’st r a n s c r i p t i o n
factor-like functions are not confined to the regulation
of viral genes but also extend to the regulation of host
cell gene expression. This has been demonstrated in the
context of B-cells where EBNA1 has been shown to
induce the expression of CD25, RAG1, RAG2 and
CCL20 [10-12] whilst in epithelial cells we have estab-
lished that expression of EBNA1 results in the differen-
tial regulation of cellular genes involved in translation,
transcription and cell signalling [13,14]. We have docu-
mented that EBNA1 enhances STAT1 expression which
sensitises cells to interferon-induced STAT1 activation,
modulates signalling in the TGFb1 pathway, and
increases AP-1 activity resulting in the enhancement of
host cell mechanisms involved in angiogenesis and
metastasis [13,14]. The mechanism whereby EBNA1
enhances AP-1 activity was determined to be via
EBNA1 binding to the promoters of the AP-1 subunits
c-Jun and ATF2 [13]. Furthermore, potential EBNA1
binding sites have been found in the promoters of
numerous other cellular genes [15].
An in silico promoter analysis of gene expression
microarray data from EBNA1-expressing carcinoma cells
revealed that 15% (362 out of 2454) of the promoters of
cellular genes differentially regulated by EBNA1 con-
tained NF-B DNA binding motifs [13,14] (and unpub-
lished data). It is well established that the EBV-encoded
LMP1 activates the NF-B cascade [3] and that the
EBV-encoded latent membrane protein 2A (LMP2A)
inhibits NF-B activity in carcinoma cell models [16].
However, the pattern of expression of these viral pro-
teins varies in NPC biopsies whilst EBNA1 is always
expressed due to its key role in EBV genome mainte-
nance. Furthermore, dysregulation of the NF-Bp a t h -
way has been implicated and documented in the
pathogenesis of a wide range of cancers [17]. These
observations coupled with reports that the functional
homologues of EBNA1 (LANA and ORF73, encoded by
KSHV and MuHV-4 respectively) inhibit NF-B activity
[18,19] prompted us to investigate whether EBNA1 also
influences NF-B activity in carcinoma cells and if this
may contribute to the development of EBV-associated
epithelial cell tumours such as nasopharyngeal carci-
noma (NPC).
Methods
Cell lines and tissue culture
Ad/AH (a human adenocarcinoma cell line derived from
the nasopharynx), Hone1 (an EBV-negative NPC cell
line), AGS (a human gastric-carcinoma derived cell line)
and derivatives stably expressing EBNA1 at levels com-
parable to those found in EBV infection, Ad/AH cells
stably infected with a recombinant EBV and C666-1 (an
EBV-positive cell line derived from an undifferentiated
EBV-positive NPC) were cultured as previously
described [13,14]. Neither Ad/AH cells stably infected
with EBV or the C666-1 cell line express the EBV-
encoded latent membrane protein 1 (LMP1). TNFa and
IL-1b (Peprotech, London, UK) were reconstituted in
serum-free growth medium to a concentration of 100
ng/ml, and stimulations carried out for 1 hour prior to
harvesting.
Luciferase assays and transient transfections
Dual luciferase reporter assays were performed accord-
ing to the manufacturer’s instructions (Promega, South-
ampton, UK, cat. no. E1980) with cells cultured as
previously described [13]. Cells were transfected with
the following plasmids using Lipofectamine (Invitrogen,
Renfrew, UK) following the manufacturer’s instructions:
pSG5-EBNA1 [20], pGL3-basic (Promega), 3 enhancer-
ConA (an NF-B-dependent luciferase reporter con-
struct in which transcription of the firefly luciferase
gene is driven by three NF-B binding sites) [21],
dnEBNA1 (M15 EBNA1 dominant-negative mutant
[22]), and a control Renilla luciferase plasmid (pRL-TK;
Promega). All assays were carried out in biological and
technical triplicate and are represented as the mean of
three independent experiments.
Construction of wild-type and mutant EBNA1 lentivirus
vectors
DNA encoding wild-type EBNA1 was excised from
pSG5-EBNA1 [20] using EcoRI and BsaHI and end-filled
using Klenow DNA polymerase. Adenine nucleotides
were added using Taq DNA polymerase and the result-
ing DNA was ligated into pCR8 (Invitrogen, cat. no.
K2500-20), following the manufacturer’si n s t r u c t i o n s .
DNA encoding the dGA, dnEBNA1 (d395-450), d8-67,
d41-376, d61-83 and d325-376 EBNA1 mutants [23]
was amplified by PCR using the following primers speci-
fic to the flanking vector sequences; 5’GCC
GGATCCCCCACTGCTTACTGGCTTAT-3’ and 5’-
GCCGTCGACGGCAAACAACAGATGGCTGGCAA-3’.
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turer’s instructions. An empty vector control (Vector)
was generated by self ligation of pCR8. The vectors
derived above were recombined with pLenti6/R4R2/V5-
DEST (Invitrogen, cat. no. K591-10 and K5910-00) and
pENTR5 containing the human metallothionein II pro-
moter, following the manufacturer’s instructions. In the
transient transfection experiments presented here zinc
stimulation was not required as the metallothionein II
promoter was found to exhibit inherent leakiness (data
not shown).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared according to the manu-
facturer’s instructions (Pierce Biotechnology, Illionois,
USA, cat. no. 78833) and EMSA analysis was carried out
on 5 μg of nuclear protein according to the manufac-
turer’s instructions (LI-COR Biosciences, Cambridge,
U K ,d o c .9 8 2 - 0 7 4 8 7 )u s i n ga nN F - B consensus probe
(sense oligonucleotide 5’-AGTTGAGGGGACTTTCC-
CAGGC-3’)w h i c hw a se i t h e r5 ’ IRDye700 labelled or
unlabelled for cold competition. EMSA gels were ana-
lysed and images were captured and quantified using
the LI-COR Odyssey infrared laser imaging system.
EMSAs were repeated for three independent biological
replicates.
TransAM analysis
Nuclear protein extracts were isolated according to
manufacturer’s instructions (Active Motif, Rixensart,
Belgium, cat. no. 40010). The NF-B subunits p65 and
p50 present in active dimers were measured using the
ELISA based TransAM NF-B family kit (Active Motif,
cat. no. 43296) according to the manufacturer’s instruc-
tion. Data are presented relative to the supplied internal
Raji cell lysate control and are represented as the mean
of three independent experiments.
RT-PCR, immunoblotting, immunofluorescence and
immunohistochemistry
RNA was extracted using EZ-RNA total RNA isolation
kit (Geneflow, Staffordshire, UK) and was reverse tran-
scribed for RT-PCR with Superscript III (Invitrogen),
following the manufacturer’si n s t r u c t i o n .R T - P C Rw a s
carried out using standard procedures with the primers
listed in Table 1. Standard immunoblotting procedures
[14] were used to detect proteins using the antibodies
listed in Table 2. All assays were carried out in biologi-
cal and technical triplicate and are represented as the
mean of three independent experiments. Tissue arrays
were constructed and assayed at the Department of
Pathology, Cancer Centre, Sun Yat-Sen University
(Guangzhou, Guangdong, China) as follows; formalin-
fixed paraffin-embedded blocks were obtained from the
archives of the Sun Yat-Sen University pathology
department. The matching H&E-stained slides were
reviewed and screened, and samples containing both
NPC tumour and adjacent nasopharyngeal mucosae
were chosen for tissue array construction. Each case was
represented by a mean of 4 cores with 2 tumours and 2
normal nasopharyngeal mucosa using a 0.6 mm punch.
Immunohistochemistry was performed using the agi-
tated low temperature epitope retrieval (ALTER)
method [24]. Immunohistochemical staining was carried
out for p65 and sections were counterstained with
haematoxylin.
Statistics
Where appropriate, statistical significance was calculated
by performing a Sudent’s t-test having first determined
equal or unequal variance by using an F-test.
Results
EBNA1 represses p65 NF-B activity in carcinoma cells
To assess whether EBNA1 influenced NF-Ba c t i v i t yw e
initially performed luciferase reporter assays in a range
of carcinoma cell lines using a synthetic NF-B reporter
and found that NF-B activity in Ad/AH, AGS and
Hone1 cells stably expressing levels of EBNA1 compar-
able to those found in EBV infection was inhibited by 8,
5 and 2.6 fold, respectively (Fig. 1). Transient expression
of EBNA1 in Ad/AH cells achieved by transfection
using a range of concentrations of EBNA1 plasmid
DNA resulted in a dose-dependent decrease in NF-B
reporter activity with a 2-fold reduction seen at the
highest concentration of input DNA (Fig. 2A). To assess
whether inhibition of NF-B required a fully functional
EBNA1, a dominant-negative EBNA1 (dnEBNA1) was
titrated against wild-type EBNA1 in Ad/AH cells.
Increasing doses of dnEBNA1, which dimerises with
Table 1 Oligonucleotide primers used in RT-PCR
Gene RT-PCR primer oligonucleotides (5’-3’)
TNFR1 Forward: GCTCCTTCACCGCTTCAGA
Reverse: CCAATGAAGAGGAGGGATAAA
TNFR2 Forward: CAGCCTTGGGTCTACTAATA
Reverse: GCCACCAGGGGAAGAATC
IL1R1 Forward: GTGATGAATGTGGCTGAAA
Reverse: CTGGGTCATCTTCATCAAT
IL1R2 Forward: CAGAGTTTTTGAGAATACAGAT
Reverse: GTCCCCCTCACACTTAGAA
C/EBPb (NF-IL6) Forward: GACTTCCTCTCCGACCTCT
Reverse: TGCTTGTCCACGGTCTTCTT
IL1a Forward: GAAGAAGAGACGGTTGAGTTT
Reverse: GCACTGGTTGGTCTTCATCT
A20 Forward: CCCAGACCACACAAGGCA
Reverse: GGCAGTATCCTTCAAACAT
EBNA1 Forward: CCGCAGATGACCCAGGAGAA
Reverse: TGGAAACCAGGGAGGCAAAT
GAPDH Forward: GCCTCCTGCACCACCAACTG
Reverse: CGACGCCTGCTTCACCACCTTCT
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almost complete abrogation of the ability of wild-type
EBNA1 to inhibit NF-B activity (Fig. 2B). In addition,
t h ed n E B N A 1a l o n eh a dn oe f f e c to nN F - Br e p o r t e r
activity (Fig. 2B). Next we performed electromobility
shift assays (EMSA) using a consensus NF-B probe to
assess whether the reduction in reporter activity was
due to a reduction in NF-B DNA binding. EMSAs per-
formed on Ad/AH cells stably expressing EBNA1 indi-
cated a 2-fold basal reduction in band intensity
indicating a reduction in nuclear protein binding to the
NF-B probe, when compared with the neo control
cells, which was consistent with our observed reduction
in reporter activity (Fig. 3). Furthermore, the ability of
two different pro-inflammatory cytokines, TNFa and IL-
1b, to enhance NF-B DNA binding was ablated in
those cells stably expressing EBNA1 (Fig. 3 and data not
shown). Similar results were observed in Ad/AH cells
stably infected with a recombinant EBV (rEBV) carrying
the neomycin drug selectable marker (Fig. 4A). In addi-
tion, the ability of TNFa, a potent activator of the cano-
nical NF-B pathway, to enhance binding with the NF-
B probe in C666-1 cells was considerably lower than in
Ad/AH parental cells (Fig. 4B). EMSAs performed on
Ad/AH cells stimulated with TNFa incubated with both
the labeled NF-B probe and a 100-fold excess of unla-
beled probe (cold competition) resulted in complete
abrogation of probe binding (Fig. 3, middle panel), thus
demonstrating the high degree of specificity in the
EMSA assays.
Having demonstrated that general NF-B activity and
NF-B DNA binding in EBNA1 expressing cells was
reduced, we sought to determine the relative abun-
dance of the canonical NF-B subunits p65 and p50 in
active nuclear complexes bound to target DNA. We
chose to study p65 and p50 because heterodimers of
these NF-Bs u b u n i t sa r et h em o s ta b u n d a n tf o r mo f
NF-B and exhibit the most powerful transcriptional
activation potential [25]. Furthermore, the canonical
NF-B pathway is most commonly associated with
innate immunity in general and with cellular differen-
tiation in epithelial cells, both of which impact upon
the pathogenesis of NPC. TransAM analysis in Ad/AH
cells demonstrated a 4-fold enrichment of p65-contain-
ing dimers in neo control cells stimulated with TNFa
(relative to un-stimulated neo cells), whereas the abun-
dance of p50 did not change significantly (Fig. 5). In
contrast, there was a 2-fold reduction in the basal
amount of p65-containing dimers in Ad/AH cells sta-
bly expressing EBNA1, when compared with the un-
stimulated neo control, and these cells were refractory
to stimulation with TNFa. However, the amount of
p50-containing dimers in Ad/AH cells stably expres-
sing EBNA1 both pre and post TNFa stimulation was
not significantly different from the levels observed in
the neo control cells. Results similar to those found in
Ad/AH cells stably expressing EBNA1 were also
observed in Ad/AH cells stably infected with rEBV and
in C666-1 cells. Interestingly, the amount of p50-con-
taining dimers was marginally increased in Ad/AH
cells stably infected with rEBV and in the C666-1 cells
and this was unaffected by stimulation with TNFa.
EBNA1 inhibits the phosphorylation and nuclear
translocation of p65 in carcinoma cells
We next sought to determine whether the EBNA1-
induced reduction in NF-B activity and reduced levels
of p65 in active NF-B dimers was as a result of
alterations in the expression or phosphorylation status
of p65. In its transcriptionally inactive form unpho-
sphorylated p65 NF-B is retained in the cytoplasm via
interactions with specific inhibitors, the IBs. Upon
stimulation of the canonical NF-B pathway the inhibi-
tory IBa protein becomes phosphorylated, ubiquiti-
nated and degraded by the 26S proteasome. NF-B
dimers subsequently translocate to the nucleus where
phosphorylated p65-containing dimers can modulate
the expression of target genes [26]. Specifically, phos-
phorylation of p65 at Ser 536 by IKKa and IKKb has
been implicated in p65 nuclear translocation and tran-
scriptional activity [26]. Immunoblot analysis con-
firmed enhanced serine 536 phosphorylation of p65
following TNFa stimulation of Ad/AH and Hone1 neo
control cells as expected (Fig. 6A and 6B, respectively).
In contrast, there was almost complete inhibition of
p65 phosphorylation in stable EBNA1-expressing Ad/
AH and Hone1 cells basally and following TNFa sti-
mulation. Furthermore, the reduction in p65 phos-
phorylation in EBNA1-expressing cells was not due to
Table 2 Antibodies used in immunoblotting (IM), immu-
nofluorescence (IF) and immunohistochemistry (IHC)
Protein Primary antibody Species Application
b-actin Sigma-Aldrich (A5441) Mouse IM
EBNA1 A.M. Human sera IM
EBNA1 R4 Rabbit IF
IKKa Santa Cruz (sc-7607) Mouse IM
IKKb Cell signalling (L570) Rabbit IM
IKKg Santa Cruz (sc-8330) Rabbit IM
IBa Cell signalling (9242) Rabbit IM
p65/RelA Cell signalling (3034) Rabbit IM
p65/RelA Santa Cruz (sc-372) Rabbit IF, IHC
Phospho-
IBa
(Ser32)
Cell signalling (2859)
Rabbit IM
Phospho-
IKKa/b
(Ser176/180)
Cell signalling (2687)
Rabbit IM
Phospho-p65 (Ser536)
Cell signalling (3031)
Rabbit IM
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Page 4 of 17Figure 1 EBNA1 inhibits NF-B luciferase reporter activity in Ad/AH (upper), AGS (middle) and Hone1 (lower) cell lines stably
expressing either EBNA1 or a neomycin control plasmid (neo). Reporter assays were performed in biological and technical triplicate and
error bars indicate SD (* = P < 0.05 relative to EBNA1-free controls).
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6B, respectively). EBNA1-expressing Hone1 cells were
also refractory to stimulation with another potent acti-
vator of the canonical NF-B pathway, IL-1b,e x h i b i t -
ing reduced p65 phosphorylation in EBNA1-expressing
cells which was in contrast to enhanced levels of phos-
pho-p65 observed in the neo control cells (Fig. 7A).
Immunofluorescence staining in Ad/AH cells also
revealed that the ability of TNFa to stimulate translo-
cation of p65 from the cytoplasm to the nucleus, as
seen in the neo control cells, was almost completely
inhibited in cells stably expressing EBNA1 (Fig. 7B).
These observations were, therefore, in agreement with
the above reporter assays, EMSA and TransAM data.
EBNA1 inhibits the phosphorylation of IBa and IKKa/b
in carcinoma cells
The activation of the canonical NF-B pathway is tightly
regulated by signals such as pro-inflammatory cytokines,
that stimulate the IB kinase complex (IKK) to phos-
phorylate the inhibitory IBs which marks them for
Ad/AH
Ad/AH
A
B
Figure 2 (A) Transient transfection of increasing concentrations of the EBNA1 expression plasmid pSG5-EBNA1 into parental Ad/AH
cells inhibits NF-B luciferase reporter activity in a dose-dependent manner. (B) Transient transfection of increasing concentrations of a
dominant-negative EBNA1 (dnEBNA1) abrogates the ability of wild-type EBNA1 (wtEBNA1) to inhibit NF-B luciferase activity in parental Ad/AH
cells. Reporter assays were performed in biological and technical triplicate and error bars indicate SD (* = P < 0.05 relative to EBNA1-free
controls).
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to translocate to the nucleus where it activates target
genes. The IKK complex is composed of two catalytic
subunits, IKKa and IKKb, which contain N- terminal
serine/threonine kinase domains and a regulatory subu-
nit, IKKg (NEMO), that does not exhibit kinase activity
but is essential for IKK phosphorylation and activation
of upstream kinases [27]. Whilst both IKKa and IKKb
cooperate for IBp h o s p h o r y l a t i o n ,I K K b is indispensa-
ble for signalling via the canonical NF-B pathway [28].
Having demonstrated that stable EBNA1 expression
results in reduced levels of phospho-p65 and its transloca-
tion to the nucleus we sought to determine whether
EBNA1 achieved this by affecting the expression and/or
phosphorylation status of the NF-B inhibitory subunit
IBa. Immunoblotting demonstrated that stable EBNA1
expression in Ad/AH and Hone1 cells resulted in a
decrease in phosphorylation of IBa at ser32, relative to
the neo control cells (Fig. 8A). In contrast, stable EBNA1
expression did not alter the expression of total IBa in the
Ad/AH
Figure 3 EMSA analysis with quantitative densitometry (lower panel) demonstrating that stable EBNA1 expression in Ad/AH cells
inhibits basal NF-B DNA binding and in response to TNFa, relative to Ad/AH cells expressing a neomycin control plasmid (neo)
(upper). Cold competition using a 100-fold excess of unlabelled NF-B probe (cold competitor) ablates NF-B binding (middle). EMSAs were
performed in triplicate.
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resulted in a marginal reduction in the expression of total
IBa, which is itself an NF-B regulated gene.
We then performed immunoblotting to determine
whether EBNA1 achieved a reduction in IBa and p65
phosphorylation by affecting components of the IKK com-
plex. There was a marked reduction in the levels of serine
phosphorylation within the activation loops of both IKKa/
b, a prerequisite for activation, in Ad/AH and Hone1 cells
stably expressing EBNA1, when compared with the neo
control cell lines (Fig. 8B). In contrast, there was no
appreciable difference in the total levels of IKKa, IKKb or
IKKg (Fig. 8B) which demonstrated that the reduction in
phospho-IKKa/b in EBNA1 expressing Ad/AH and
Hone1 cells was not due to a reduction in the expression
of these catalytic subunits.
Deletion of EBNA1 domains required for transactivation
of EBV encoded genes abrogates the ability of EBNA1 to
inhibit NF-B activity
Having demonstrated that EBNA1 inhibited the phos-
phorylation of IKKa/b we asked whether specific
domains of EBNA1 were responsible for this
A
B
Figure 4 EMSA analysis with quantitative densitometry demonstrating that (A) Ad/AH cells stably infected with rEBV exhibit reduced
NF-B DNA binding, both basally and in response to TNFa, relative to Ad/AH parental cells. (B) C666-1 cells (EBV-positive) exhibit
reduced NF-B DNA binding, both basally and in response to TNFa, relative to Ad/AH parental cells. EMSAs were performed in triplicate.
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and a selection of EBNA1 domain mutants [23] into a
lentiviral expression vector. Amounts of DNA found to
yield equal levels of protein expression (data not shown)
were transiently transfected into Ad/AH cells and NF-
B luciferase reporter assays were performed (Fig. 9).
Transfection of wild-type EBNA1 (wtEBNA1) and
EBNA1 lacking the gly-ala repeat region (dGA), from
which all subsequent mutants were derived [23],
resulted in a significant reduction in NF-B activity,
relative to the empty vector control (Vector), in agree-
ment with our data presented in Fig. 2A. Transfection
of a dominant-negative EBNA1 (dnEBNA1) carrying the
same DNA sequence as that used in Fig. 2B did not
result in a significant reduction in NF-B reporter activ-
ity. Transfection of EBNA1 mutants d8-67, d41-376,
d61-83 and d325-376 did not result in a significant
r e d u c t i o ni nN F - B reporter activity. Thus deletion of
domains of EBNA1 essential to its ability to transacti-
vate viral gene expression ablated its ability to inhibit
NF-B activity. In contrast, transfection of an EBNA1
mutant deleted for the binding site of the
deubiquitinylating enzyme USP7 [4] (d395-450) resulted
in significant inhibition of NF-B reporter activity.
Therefore deletion of the USP7 binding domain had not
altered the ability of EBNA1 to inhibit NF-Ba c t i v i t y .
These data therefore suggested that the mechanism by
which EBNA1 was able to inhibit phosphorylation of
IKKa/b was likely to be through EBNA1s ability to
modulate the expression of cellular genes. Therefore we
sought to determine whether EBNA1 influenced the
expression of a selection of genes reported to regulate
IKK activity and the canonical NF-B pathway in
general.
EBNA1 does not alter the expression of IL-1 or TNF
receptors in carcinoma cells
As IL-1 and TNF activate the canonical NF-Bp a t h w a y
by binding with their cognate receptors we next exam-
ined whether the EBNA1-induced reduction in IKKa/b
phosphorylation was as a consequence of EBNA1 modu-
lating the expression of IL-1 and/or TNF receptors. RT-
PCR analysis revealed that EBNA1 did not alter the nat-
ural levels of expression of the IL-1 receptors 1 and 2
(IL1R1 and IL1R2) or TNF receptors 1 or 2 (TNFR1
Figure 5 TransAM analysis demonstrating the p65 and p50 composition of transcriptionally competent NF-B dimers present in Ad/
AH cells stably expressing EBNA1 or a neomycin control vector (neo), Ad/AH cells stably infected with rEBV and C666-1 cells, under
basal conditions and following stimulation with 100 ng/ml TNFa. TransAM analysis was performed in biological and technical triplicate and
error bars indicate SD (* = P < 0.05 relative to Ad/AH Neo control).
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Therefore it is unlikely that EBNA1 modulates NF-B
by influencing the ability of cells to respond to these
pro-inflammatory ligands.
EBNA1 does not inhibit NF-B activity through down-
regulation of pro-inflammatory cytokines or up-regulation
of C/EBPb or A20
We next sought to determine whether EBNA1 inhib-
ited NF-B activity by down-regulating the expression
of IL-1 and TNFa. RT-PCR demonstrated that whilst
TNFa and IL-1b expression could not be detected we
surprisingly found IL-1a to be up-regulated by EBNA1
in both Ad/AH and Hone1 cells (Fig. 10B and micro-
array data not shown). This suggested that reduced sti-
mulation of the NF-B pathway is not responsible for
the low levels of NF-B activity observed in EBNA1
expressing epithelial cells. Intriguingly, however, ele-
vated IL-1a is a marked feature of NPC suggesting
that EBNA1 may contribute to this phenotype [29,30].
The transcription factor C/EBPb has been implicated
in NF-B inhibition by preventing p65 phosphorylation
[31]. RT-PCR revealed that EBNA1 expression in the
nasopharyngeal cell lines was associated with C/EBPb
down-regulation and was therefore unlikely to be
A
B
Figure 6 EBNA1 inhibits p65 phosphorylation in carcinoma cell lines. Western blot analyses of total and phosphorylated (ser 536) p65 in (A)
Ad/AH and (B) Hone1 cells stably expressing EBNA1 or a neomycin control vector (neo) under basal conditions or following stimulation with
TNFa. Western blotting for EBNA1 and b-actin serve as EBNA1 expression and protein loading controls, respectively.
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Figure 7 EBNA1 inhibits p65 phosphorylation and nuclear translocation in carcinoma cell lines. Western blot analyses of total and
phosphorylated (ser 536) p65 in (A) Hone1 cells stably expressing EBNA1 or a neomycin control vector (neo) under basal conditions or following
stimulation with IL-1b. Western blotting for EBNA1 and b-actin serve as EBNA1 expression and protein loading controls, respectively. (B)
Immunofluorescent staining for p65 in Ad/AH cells stably expressing EBNA1 or a neomycin control vector (neo) under basal conditions or
following stimulation with 100 ng/ml TNFa.
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Figure 8 EBNA1 inhibits the phosphorylation of IBa and IKKa/b in carcinoma cells. (A) Western blot analysis of total and phosphorylated
IBa (ser32) in Ad/AH and Hone1 cells stably expressing EBNA1 or a neomycin control vector (neo).(B) Western blot analysis of total IKKa, IKKb,
IKKg and phosphorylated IKKa/b (IKKa Ser176/180 and IKKb Ser177/181) in Ad/AH and Hone1 cells stably expressing EBNA1 or a neomycin
control vector (neo). Western blotting for EBNA1 and b-actin serve as EBNA1 expression and protein loading controls, respectively.
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NF-B activity in epithelial cells (Fig. 10B).
T h em i c r o a r r a yd a t au s e df o rt h ein silico promoter
analysis that implicated EBNA1 as having a role in NF-
B modulation reported that expression of A20, which
inhibits NF-B machinery up-stream of the IKK com-
plex, was up-regulated 2.5-fold. RT-PCR analysis, how-
ever, indicated that A20 was down-regulated in Ad/AH
and Hone1 cells stably expressing EBNA1 and was
therefore unlikely to be involved in the mechanism by
which EBNA1 inhibited NF-B activity in epithelial cells
(Fig. 10B)
p65 is localised to the cytoplasm in NPC tumour cells
Previous reports have demonstrated in EBV-positive
NPC xenografts and EBV-positive NPC biopsies that
p65 is localised to the cytoplasm in tumour cells [32,33].
Having demonstrated that there was a reduction in
active nuclear p65 in carcinoma cells stably expressing
EBNA1, infected with rEBV and in C666-1 cells we
sought to confirm the p65 status in NPC biopsies.
Immunohistochemical staining for p65 was carried out
on tissue arrays containing 11 NPC biopsies with
matched normal nasopharyngeal control tissue. This
demonstrated that the level of p65 staining was elevated
in the tumour cells of 6 out of 11 NPC biopsies, relative
to the matched normal tissue sections, with the p65
staining in the remaining 5 tumour samples being indis-
tinguishable from the controls. However, the p65 stain-
ing in all cases was exclusively cytoplasmic with no
detectable nuclear staining despite the pro-inflammatory
environment characteristic of NPC. The p65 staining in
the cellular infiltrate of all NPC biopsies was negative.
Two examples are presented in Fig. 11.
Discussion
NF-B signalling regulates a variety of major cellular
processes, including cell growth, differentiation and
apoptosis, and it is therefore not surprising that aberrant
NF-B signalling has been implicated and documented
in the pathogenesis of a wide range of cancers. In addi-
tion, NF-B signalling impacts upon both adaptive and
innate immunity, the latter being crucial to the ability of
host cells to mount effective defences against oncogenic
viruses such as EBV [34]. In this study we have demon-
strated for the first time that NF-B activity is repressed
by both transient and stable expression of EBNA1 in a
number of carcinoma cell lines; confirming that the phe-
nomenon is not merely cell line specific or due to clonal
variation. This study therefore reveals that, like its
homologues from KSHV and MuHV-4 (LANA and
ORF73, respectively) [18,19], EBNA1 also has a role in
inhibiting the NF-B pathway and that this is therefore
most likely a conserved function amongst these gamma-
herpesvirus nuclear proteins.
Whilst the mechanism for ORF73-mediated NF-B
inhibition has been determined to be via poly-ubiquiti-
nation and subsequent proteasomal-dependent nuclear
degradation of p65, which is dependent upon a SOCs
box motif present in ORF73, the mechanism for LANA-
mediated NF-B repression remains unknown, although
it may be similar as LANA also contains a SOCs box
[19,35]. However, examination of EBNA1 reveals no
obvious SOCs motif. In contrast, the findings presented
Figure 9 NF-B luciferase reporter activity following transient transfection of Ad/AH cells with concentrations of lentivirus vectors
that result in equal levels of expression of wild-type EBNA1 and mutants. Wild-type (wtEBNA1), gly-ala repeat-deleted EBNA1 (dGA) and
EBNA1 deleted for the cellular USP7 binding site (d395-450 dUSP7) result in significant inhibition of NF-B reporter activity, relative to the empty
vector control (Vector). In contrast, deletion of EBNA1 domains (d8-67, d41-376, d61-83 and d325-376) characterised as being essential for the
transactivation of EBV genes does not result in inhibition of NF-B reporter activity. Reporter assays were performed in biological and technical
triplicate and error bars indicate SD (* = P < 0.05 relative to empty vector control).
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pathway in carcinoma lines by inhibiting phosphoryla-
tion of the IKK complex upon which several pro-inflam-
matory signalling cascades converge, enabling EBNA1 to
block NF-B activation in response to a broad range of
stimuli.
Whilst we have not fully elucidated the mechanism by
which EBNA1 inhibits IKK phosphorylation our data do
indicate that deletion of domains of EBNA1 reported to
be essential to its ability to transactivate EBV encoded
genes [23] abrogated the ability of EBNA1 to inhibit
NF-B activity, whereas deletion of the domain of
EBNA1 known to bind with the cellular deubiquitinylat-
ing enzyme USP7 [4] had no effect. These data therefore
suggest that the ability of EBNA1 to inhibit IKK phos-
phorylation is most likely via EBNA1 regulating the
expression of a cellular gene(s) involved in this process.
Subsequent RT-PCR analysis determined that a reduc-
tion in IKKa/b phosphorylation was not likely to be as
a result of inhibition of the expression of IL-1 or TNFa
receptors or their ligands, or by up-regulation of the
NF-B inhibitors C/EBPb or A20. Interestingly, RT-PCR
analysis indicated that A20 was down regulated in Ad/
AH and Hone1 cells stably expressing physiological
levels of EBNA1, adding credence to our observations
that EBNA1 inhibits NF-B activity as A20 expression is
positively regulated by NF-B [36]. In addition, preli-
minary observations suggest that EBNA1 does not bind
with or relocalise IKKb to the nucleus and so it is unli-
kely that this is the mechanism by which nuclear
EBNA1 inhibits the phosphorylation and activity of the
IKK complex (Figure S1, Additional file 1). The precise
mechanism by which EBNA1 inhibits IKKa/b phosphor-
ylation and NF-B activity is therefore currently under
investigation.
Chronic activation of NF-Bi sa s s o c i a t e dw i t ht h e
development of a number of malignancies. Therefore on
face value our observation that EBNA1 inhibits canoni-
cal NF-B would appear counter intuitive with regard to
the pathogenesis of NPC. However, within the context
of epithelial cells it has been reported that NF-Ba c t i -
vation is growth inhibitory. For example, Seitz et al. [37]
found that the expression of constitutively active p50
and p65 canonical NF-B subunits in normal epithelial
cells resulted in irreversible cell cycle arrest, whereas
Gapuzan et al. [38] reported that p65 knockout fibro-
blasts have a transformed phenotype. In addition,
expression of a dominant-negative IBa “super repres-
sor” in murine and human epidermis led to hyperplasia
and the development of squamous cell carcinoma (SCC)
[39]. Furthermore, Dajee et al. [40] showed in SCC
biopsies that p65 staining was predominantly cytosolic.
The ability of EBV-encoded LMP1 to activate both the
canonical and non-canonical NF-B pathway has been
the subject of many, mostly in vitro, studies. However it
is becoming increasingly evident that the ability of
LMP1 to activate the NF-B cascade in vivo where
other EBV latent genes, including EBNA1, are expressed
is not so well defined. Recent studies have gone some
way to addressing this question by demonstrating in
EBV-positive NPC biopsies and xenografts that p65 is
located almost exclusively in the cytoplasm and that this
is independent of LMP1 expression [32,33]. In agree-
ment with and expanding upon these data, we have
demonstrated that whilst the level of p65 was elevated
in 6 out of 11 NPC tumours examined, relative to
matched normal control tissue from the same patient, in
all cases p65 staining was cytoplasmic. Thornburg et al.
[33] propose that inhibition of p65 in NPC may protect
against growth arrest whilst p50/p50 and p50/BCL3 NF-
B could still maintain the tumourigenic effects of NF-
B. It is therefore interesting to speculate that EBNA1
m a ym o d u l a t et h ea b i l i t yo fL M P 1t oa c t i v a t es p e c i f i c
aspects of NF-B signaling and that this in turn may
impact upon the pathogenesis of NPC and other EBV-
related tumours. This clearly warrants further
investigation.
Conclusions
Our findings suggest that EBNA1 may play a role in the
inhibition of p65 NF-Bi nN P Ca n dt h a tt h i sc o u l d
contribute to NPC pathogenesis by inducing tissue
hyperplasia. Viruses have evolved an array of mechan-
isms to overcome the induction of NF-Ba saw a yo f
evading the innate immune response [34,41-43]. We
therefore propose that inhibition of canonical NF-Bb y
EBNA1 may not only contribute to the development of
tissue hyperplasia but may also play a role in the patho-
genesis of NPC via evasion of host immune responses
during early EBV infection.
Additional file 1: Figure S1: EBNA1 does not bind with or relocalise
IKKb to the nucleus in Ad/AH cells. A PowerPoint file demonstrating
that EBNA1 does not bind with or relocalise IKKb to the nucleus in Ad/
AH cells. (A) Pseudo-wild type EBNA1 (with deleted Gly/Ala repeat
region) fused to the HaloTag protein (N-terminal) in the pFC14K-CMV
backbone plasmid (Halo-EBNA1) (Promega UK, to be described
elsewhere) was transiently transfected into Ad/AH cells. Following pull-
down of Halo-EBNA1 using affinity resin samples were washed following
the manufactures instructions and subjected to immunoblotting for
EBNA1, the known cellular EBNA1 binding protein USP7 and IKKb. Input
= whole protein lysate prior to Halo-EBNA1 pull-down, BL = pull-down
resin blocked with the supplied blocking ligand, No BL = Halo-EBNA1
pull-down using the supplied resin without the use of the blocking
ligand. (B) Immunoblotting for IKKb was carried out on nuclear and
cytosolic extracts from Ad/AH cells stably expressing either EBNA1 or a
neomycin control vector (neo). Immunoblotting for SP1 and tubulin was
carried out to demonstrate adequate fractionation of nuclear and
cytosolic extracts, respectively.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-1-
S1.PPT]
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Figure 10 RT-PCR analysis for (A) the interleukin-1 receptors 1 and 2 (IL1R1 and IL1R2), TNF receptors 1 and 2 (TNFR1 and TNFR2) in
Ad/AH and Hone1 cells stably expressing EBNA1 or a neomycin control vector (neo) indicate that EBNA1 does not alter the natural
level of expression of IL-1 or TNF receptors in carcinoma cells. (B) RT-PCR analysis for IL-1a, C/EBPb and A20 in Ad/AH and Hone1 cells
stably expressing EBNA1 or a neomycin control vector (neo) indicate that EBNA1 does not inhibit NF-B activity through down-regulation of
pro-inflammatory cytokines or up-regulation of C/EBPb or A20. RT-PCR for EBNA1 and GAPDH serve as EBNA1 and loading controls, respectively,
whilst the water only sample (H2O) serves as a general PCR control.
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Figure 11 In the tumour cells of NPC biopsies p65 is localised in the cytoplasm. Immunohistochemical staining for p65 was carried out on
tissue arrays containing 11 NPC biopsies with matched normal nasopharyngeal control tissue isolated from the same patients. Two examples of
this staining (A and B) are presented where black arrows indicate tumour cell islands and white arrows indicate the cellular infiltrate surrounding
tumour cells. A higher magnification of the cells bounded by a black box in (B) is presented in (C) where the black arrow indicates the
cytoplasm and the white arrow indicates the nucleus. Sections were counterstained with haematoxylin.
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